A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Status:
Recruiting
Trial end date:
2024-04-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the relative bioavailability (rBA; Period 1) and
bioequivalence (BE; Period 2 and 3) of various strengths and formulations of niraparib and
abiraterone acetate (AA) at steady state under modified fasted conditions in participants
with metastatic castration-resistant prostate cancer (mCRPC).